Layout of GAIABONE in Singapore

On 26th March, Dr Sun Yang, the founder of Corliber, was invited to the Orthopaedic Department of Yishun Community Hospital in Singapore to give a lecture on GAIABONE in the department meeting, which was attended by more than 20 doctors from the Orthopaedic Department of Yishun Community Hospital.

At the beginning of the presentation, Dr Sun Yang gave a brief introduction of himself and the company. Dr Sun's NUS doctoral research experience immediately drew the distance between Corliber and all the doctors present. After listening to the presentation, the doctors asked questions enthusiastically and expressed their strong interest in the properties of GAIABONE, which made the atmosphere of the meeting very good and enthusiastic.

Currently, the registration of GAIABONE with the Health Science Authority of Singapore is progressing smoothly. Before GAIABONE receives the official marketing approval, Yishun Community Hospital has taken the lead in applying for the Special Authorisation Route to introduce GAIABONE for clinical application in the hospital.

As the largest public community hospital in Singapore, Yishun Community Hospital's initiative is a high recognition of Corliber's product development and quality control of GAIABONE, which is the first time that Corliber has taken an eye-catching first step on behalf of China's biomaterials brands in Singapore, where the regulation is extremely stringent and the majority of the brands are from Europe and the United States. In the near future, GAIABONE will formally cover all major hospitals in Singapore, and this crystallisation of the China-Singapore collision of science and technology and industry will be based in Singapore and will reach out to nearly 700 million people in Southeast Asia.